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Syringa oblata Lindl. Aqueous
Extract Is a Potential Biofilm Inhibitor
in S. suis
Jingwen Bai†, Yanbei Yang†, Shuai Wang, Lingfei Gao, Jianqing Chen, Yongzhi Ren,
Wenya Ding, Ishfaq Muhammad and Yanhua Li*
College of Veterinary Medicine, Northeast Agricultural University, Harbin, China
Streptococcus suis (S. suis) is a zoonotic pathogen that causes severe disease
symptoms in pigs and humans. Syringa oblata Lindl. distributed in the middle latitudes
of Eurasia and North America were proved as the most development potential of
Chinese Medicine. In this study, biofilm formation by S. suis decreased after growth
with 1/2 MIC, 1/4 MIC, or 1/8 MIC of Syringa oblata Lindl. aqueous extract and rutin.
Scanning electron microscopy analysis revealed the potential effect of Syringa oblata
Lindl. aqueous extract and rutin against biofilm formation by S. suis. Using iTRAQ
technology, comparative proteomic analyses was performed at two conditions: 1/2
MIC of Syringa oblata Lindl. aqueous extract treated and non-treated cells. The results
revealed the existence of 28 proteins of varying amounts. We found that the majority of
the proteins were related to cell growth and metabolism. We also found that Syringa
oblata Lindl. Aqueous extract affected the synthesis enzymes. In summary, Syringa
oblata Lindl. aqueous extract might be used to inhibit the biofilm formation effectively
by S. suis, and the active ingredients of the Syringa oblate Lindl. aqueous extract is
rutin. The content of rutin is 9.9 ± 0.089 mg/g dry weight.
Keywords: proteomics, Streptococcus suis, Syringa oblata Lindl., biofilm formation
INTRODUCTION
Streptococcus suis (S. suis) is a major bacterial pathogen of young pigs and a worldwide economic
problem for the pig industry (Goyette-Desjardins et al., 2014). Furthermore, S. suis is emerging as
a zoonotic pathogen associated with meningitis and septicaemia in humans (Ferrando et al., 2014).
In one often-cited statistic sourced from the US National Institutes of Health (NIH), biofilms are
indicated as the cause of>60% of all clinical microbial infections (Abbanat et al., 2014). Moreover,
some studies have demonstrated that S. suis has the ability to form biofilms (Brown et al., 1988;
Brady et al., 2008). Biofilms are defined as consortia of microorganisms that are attached to a biotic
or abiotic surface. In addition, microorganisms embedded in the biofilm offers more resistant to
desiccation, environmental stress (nutritional or oxidative stress), and UV lightexposure (Lee et al.,
2008; Rao et al., 2008).
The S. suis serotypes are determined by the antigenicity of capsule. To date, S. suis have 33
serotypes according to antigenic differences in the capsular polysaccharide (CPS) (Wang et al.,
2011). The cps genes code for the production of capsule (Smith et al., 1999). S. suis serotyping
based on variation in the capsule structures encoded by cps locus genes accountable for capsule
formation (Liu et al., 2013).
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Now days, the majority of drugs produced from naturally
occurring molecules, especially the anti-infective agents.
Newman and Cragg surveyed that natural products, or drugs
obtained from natural product scaffolds, account for >75% of
the 97 accepted antibacterial New Chemical Entities intercalate
over the period 1981–2006, shows the significance of natural
products used in clinics against infectious diseases (Taylor, 2013).
The discovery of new drugs for curing various diseases mostly
comes from biologically active natural products, especially the
plant-derived ones (Coleman et al., 2010; Koh et al., 2013).
Particularly, some plants grow in an environment that has
high bacterial density and so they have co-existed with bacteria
during their evolution. Accordingly, the plants may have evolved
protective mechanisms against bacterial infections, and may
even produce bacterial biofilm inhibitors (Zhu et al., 1998; Ding
et al., 2011). Folium syringae leaves are mainly from the dry
leaves of Oleaceae plant: Syringa oblate Lindl., Syringa diatata
Nakai and Syringa vulgaris L., which were proved as the most
development potential of Chinese Medicine through its plant
resources, chemical constituents, pharmacological action and
clinical application. Syringa has been widely cultivated in the
northern parts of China and Korea. The traditional Chinese
treatment uses the leaf, flowerbud, and bark of Syringa to treat
various infections, heal inflammations, dampness and acute
icteric hepatitis (Feng et al., 2009). In Korea, the stem bark of
Syringa has been used for the treatment of tooth pain, intestinal
disorders and diarrhea (Park et al., 1999).
We have analyzed the relationship between the spectrum and
the impact of Syringa oblata Lindl. aqueous extract on S. suis
biofilms in vitro. According to HPLC fingerprint and anti-biofilm
activity test, gray relational analysis was applied to find the
active compositions. According to the relational grade, rutin
make significant contribution to anti-biofilm activity. Rutin is a
well-known and widely used citrus flavonoid glycoside between
flavonol quercetin and disaccharide rutinose. It is found in
many foods, such as buckwheat, onion, lemon, apple, orange,
and grapefruit. Rutin has a lot of benefit pharmacological
effects, such as anti-inflammatory, antimicrobial, antioxidant,
and antihypertensive effects (Erlund et al., 2000; Middleton et al.,
2000).
Our laboratory recently reported that sub-MICs of emodin
and sub-MICs of erythromycin inhibited biofilm formation by
S. suis ATCC 700794 (Yang et al., 2015; Zhao et al., 2015).
However, the relationship between Syringa oblata Lindl. and
biofilm formation by S. suis remains poorly understood. The
objective of this study was to search new potential inhibitors for
the control of biofilm formation by S. suis; and to describe the use
of proteomics to better understand the impact of Syringa oblata
Lindl. aqueous extract on S. suis biofilms in vitro.
MATERIALS AND METHODS
Preparation of Syringa oblata Lindl.
Aqueous Extract
Syringa oblata Lindl. was collected in Northeast Agricultural
University (Harbin, Heilongjiang, China). Taxonomic identi-
fication was confirmed by Professor Xiuju Wu (Heilongjiang
University of traditional Chinese Medicine, Harbin, China).
A coarsely powdered, air-dried, Syringa oblata Lindl. (leaves,
200 g) was boiled in 2 L of distilled water for 45 min, decanted
and filtered. The filtrate was evaporated to dryness in an oven set
at 60◦C. The dried Syringa oblata Lindl. extract was weighed and
reconstituted to a concentration of 100 mg/mL.
HPLC and HPLC-ESI-MS Analysis of
Syringa oblata Lindl. Aqueous Extract
On-line HPLC measurements were performed on Waters
Alliance HPLC system (Shimadzu Corporation, Kyoto,
Japan) consisting of a binary pump and a UV/V is detector.
The separation was achieved using a DL-Cl8 column
(4.6 mm × 250 mm, 5 µm, Japan) at 25◦C. The mobile
phase was composed of acetonitrile (A) and 0.1% formic acid
(B). The rate of flow was 1.0 mL/min. The volume injected was
20 µL and the detection wavelength was 245 nm.
For LC–MS analysis, the Agilent 3000 HPLC system was
coupled on-line to an LC/MSD Trap SL Plus spectrometer
(Agilent, Corp., Massachusetts, American) equipped with
electrospray ionization (ESI) source. In order to ionize the target
compound, ESI in both positive- and negative-ion modes was
investigated. The MS was operated in MRM mode, and the
capillary voltage and the ion spray voltage were set at 3.0 and
5.5 kV, respectively. Ultrahigh-purity helium was used as the
collision gas (10 p.s.i.) and high-purity nitrogen as the nebulizing
gas (12 p.s.i.). The source temperature was set at 300◦C. For full
scan MS analysis, the spectra were recorded in the range m/z
100–1000.
Identification and Quantification of Rutin
Rutin in the Syringa oblata Lindl. aqueous extract was identified
by comparing its mass spectrum with literature data (Regos et al.,
2009; Zhao et al., 2013), and comparing the HPLC retention time
with that of the authentic standard. Quantification of rutin in the
aqueous extract was carried out based on linear calibration plot
of the peak area in HPLC at 245 nm against concentration using
the external standard method.
Experimental Bacterial Strain and
Culture Conditions
Streptococcus suis ATCC 700794 was used in this study. Bacteria
were cultured at 37◦C in Todd-Hewitt broth (THB; Summus,
Ltd, Harbin, Heilongjiang, China) or Todd-Hewitt broth agar
(THA) added with 5% (v/v) fetal bovine serum (Sijiqing,
Ltd, Hangzhou, Zhejiang, China). In order to obtain THA,
The original THB was added with 1.8% Bacto-agar (Difco
Laboratories). The media were sterilized in autoclave (30 min
at 115◦C) and before inoculation, all strains were transferred
from the stock cultures to THA and incubated aerobically at
37◦C for 16 h. Then, all strains were sub-cultured one more
time under the same conditions. The cultures were used for the
minimal inhibitory concentration (MIC) assays and the biofilm
assays.
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Determination of MIC
Minimal inhibitory concentration of Syringa oblata Lindl.
aqueous extract and rutin (dissolved in Methanol) (Guoyao,
Ltd, China) was determined three times using the protocol
described by Wiegand et al. (2008), with a few modifications.
Briefly, The sterile saline solutions were used for the dilution
of overnight cultures of S. suis to obtain the turbidity of a
so-called McFarland 0.5 standard (corresponding to 1 × 108
colony-forming units [CFUs]/mL). Then, 5% (v/v) fetal bovine
serum was added to sterile THB to dilute the cultures of S. suis
(1:100). 100 µL of each sample was added to the wells of
a Costar R©3599 96-well plate (Corning, NY, USA) containing
serial dilutions of Syringa oblata Lindl. aqueous extract and
rutin in culture medium (100 µL). Bacteria grown as control
were cultured in the absence of Syringa oblata Lindl. aqueous
extract and rutin. After incubation for 24 h at 37◦C, the MIC
was determined as the lowest concentration of Syringa oblata
Lindl. aqueous extract and rutin that completely inhibited S. suis
growth.
Biofilm Assay
Streptococcus suis strain was cultured overnight and diluted to
an optical density of 0.1 at 660 nm (OD 660). Same amount
of S. suis was grown in a Costar R© 3599 96-well plate in the
presence of 1/2 MIC, 1/4 MIC, 1/8 MIC, or 1/16 MIC of
Syringa oblata Lindl. aqueous extract and rutin. S. suis ATCC
700794 treated without Syringa oblata Lindl. aqueous extract
and rutin was served as a control. Biofilms were treated as
described by Yang et al. (2015) with some modifications. Briefly,
the medium, free-floating bacteria, and loosely bound biofilm
were removed by aspiration, and the wells were washed thrice
with sterile physiological saline. The remaining bacteria were
fixed with 200 µL methanol (99%) (Guoyao, Ltd, China) per
well, and after 15 min, plates were dried and emptied. Then,
plates were stained for 5 min with 200 µL crystal violet (2%)
(Guoyao, Ltd, China) per well. The excess stain was washed
with water. Then the dye was resolubilized with 200 µL glacial
acetic acid (33%) (Guoyao, Ltd, China) per well. A microplate
reader (DG5033A, Huadong, Ltd, Nanjing, Jiangsu, China) was
used to quantify the amount of released stain at absorbance of
570 nm.
Scanning Electron Microscopy (SEM)
Scanning electron microscope (SEM) was used to examine the
S. suis biofilm (refer to Bedran et al., 2014). Briefly, 1 mL of S. suis
were diluted to an optical density of 0.1 at 600 nm (OD600) in
culture without Syringa oblata Lindl. aqueous extract or with 1/2
MIC of Syringa oblata Lindl. aqueous extract was added into wells
of a 6-well plate containing glass slide. The same condition was
treated for rutin. After 24 h incubation, medium and free-floating
bacteria were removed. The biofilms were incubated overnight
in fixation buffer (4% (w/v) paraformaldehyde, 2.5% (w/v)
glutaraldehyde, 2 mM CaCl2 in 0.2 M cacodylate buffer, pH 7.2),
washed with 0.1 M cacodylate buffer pH 7.0 (3 min × 20 min)
and post-fixed for 90 min at room temperature in 1% (w/v)
osmic acid containing 2 mM potassium ferrocyanide and 6%
(w/v) sucrose in cacodylate buffer. The samples were dried,
gold sputtered with an ion sputtering instrument (current
15 mA, 2 min) and finally observed using SEM (FEI Quanta,
Netherlands).
Protein Digestion and iTRAQ Labeling
Protein was extracted from S. suis cells at two different conditions
(1/2 MIC of Syringa oblata Lindl. aqueous extract treated cells
and non-treated cells). iTRAQ analysis was implemented at
Shanghai Applied Protein Technology, Co. Ltd (APT, Shanghai,
China). Three biological replicates were evaluated to minimize
the influence of less reliable quantitative information.
Protein digestion was carried out according to the reported
FASP procedure (Wisniewski et al., 2009). Briefly, 200 µg of
proteins for each sample were incorporated into 30 µL STD
buffer (4% SDS, 100 mM DTT, 150 mM Tris-HCl pH 8.0). The
detergent, DTT and other low-molecular-weight components
were removed using UA buffer (8 M Urea, 150 mM Tris-HCl
pH 8.0) by repeated ultrafiltration (Microcon units, 30 kD).
Then 100 µL 0.05 M iodoacetamide in UA buffer was added to
block reduced cysteine residues and the samples were incubated
for 20 min in the dark. The filters were washed three times
with 100 µL UA buffer and two times with 100 µL DS buffer
(50 mM triethylammoniumbicarbonate at pH 8.5) respectively.
Then, the protein suspensions were digested with 2 µg trypsin
(Promega) in 40 µL DS buffer overnight at 37◦C, and the filtrate
(peptides) were collected. The peptide content was quantified
by UV light spectral density at 280 nm using an extinctions
coefficient of 1.1 of 0.1% (g/l) solution that was calculated on the
basis of the frequency of tryptophan and tyrosine in vertebrate
proteins.
For the iTRAQ labeling, the peptides were labeled with the 8-
plex iTRAQ reagent by following the manufacturer’s instructions
(Applied Biosystems). Each iTRAQ reagent was dissolved in
70µL of ethanol and added to the respective peptide mixture. The
peptides from the S. suis biofilms treated by Syringa oblata Lindl.
aqueous extract were labeled with 115 isobaric reagent, and the
peptides from the non-treated S. suis biofilms were labeled with
116 isobaric reagent. Then, the samples were multiplexed and
vacuum dried. Three independent biological experiments were
performed.
Peptide Fractionation with Strong Cation
Exchange (SCX) Chromatography
Strong cation exchange (SCX) chromatography AKTA Purifier
system (GE Healthcare) was used for iTRAQ labeled peptides
fractionation. The dried peptide mixture was reconstituted
and acidified with 2 mL buffer A (10 mM KH2PO4 in
25% of ACN, pH 2.7) and loaded onto a PolySULFOETHYL
4.6 mm × 100 mm column (5 µm, 200 Å, PolyLC, Inc.,
Columbia, MD, USA). The peptides were eluted at a flow rate
of 1 ml/min with a gradient of 0–10% buffer B (500 mM KCl,
10 mM KH2PO4 in 25% of ACN, pH 2.7) for 2 min, 10–20%
buffer B for 25 min, 20–45% buffer B for 5 min, and 50–
100% buffer B for 5 min. The separation was monitored by
absorbance at 214 nm, and the fractions were collected after
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every 1 min. The obtained fractions (approximately 30 fractions)
were combined into 10 pools and desalted on C18 Cartridges
[EmporeTM SPE Cartridges C18 (standard density), bed I.D.
7 mm, volume 3 ml, Sigma]. All fractions were concentrated by
vacuum centrifugation and reconstituted in 40 µL of 0.1% (v/v)
trifluoroacetic acid. And samples were stored at −80◦C until
LC–MS/MS analysis.
Liquid Chromatography (LC) –
Electrospray Ionization (ESI) Tandem MS
(MS/MS) Analysis by Q Exactive
Q Exactive mass spectrometer was used for experiments that were
coupled to Easy nLC (Proxeon Biosystems, now Thermo Fisher
Scientific). Each fraction (10 µL) was injected for the nanoLC–
MS/MS analysis. The peptide mixture (5 µg) was loaded onto
a C18-reversed phase column (Thermo Scientific Easy Column,
10 cm long, 75 µm inner diameter, 3 µm resin) in buffer A (0.1%
formic acid) and separated with a linear gradient of buffer B (80%
acetonitrile and 0.1% formic acid) at a flow rate of 250 nl/min
controlled by IntelliFlow technology over 140 min. MS data
were acquired using a data-dependent top10 method dynamically
choosing the most abundant precursor ions from the survey
scan (300–1800 m/z) for HCD fragmentation. Determination of
the target value is based on predictive Automatic Gain Control
(pAGC). Dynamic exclusion duration was 60 s. Survey scans were
acquired at a resolution of 70,000 at m/z 200, and resolution
for HCD spectra was fixed at 17,500 at m/z 200. 30 eV was
normalized collision energy and the underfill ratio, which shows
the minimum percentage of the target value likely to be reached
at maximum fill time, was defined as 0.1%. The experiment run
with the peptide recognition mode enabled.
Sequence Database Searching and Data
Analysis
The MS/MS spectra were searched using the MASCOT engine
(Matrix Science, London, UK; version 2.2) in the Proteome
Discoverer 1.3 (Thermo Electron, San Jose, CA, USA) against
Uniprot Streptococcus suis. fasta database (uniprot streptococcus
suis. fasta, 38369 sequences, downloaded at November 4th, 2013)
and the decoy database. The following options were used for
protein identification. MS/MS tolerance = 0.1 Da, Peptide mass
tolerance = 20 ppm, Enzyme = Trypsin, Missed cleavage = 2,
Fixed modification: Carbamidomethyl (C), iTRAQ 8plex (K),
iTRAQ 8plex (N-term), Variable modification:Oxidation (M),
FDR ≤ 0.01.
Statistical Analysis
Assays were run in triplicate and the mean ± standard deviation
were calculated. Data were analyzed using the Student’s t-test.
RESULTS AND DISCUSSION
Identification and Quantification of Rutin
in Syringa oblata Lindl. Aqueous Extract
The chromatographic characteristics of the compound such as
retention time and molecular ions were established under the
experimental conditions to determine the rutin in Syringa oblata
Lindl. aqueous extract. The typical HPLC chromatograms of
sample solution and standard rutin solution were shown in
Figure 1. As could be seen, the retention time of the rutin
in sample was in good agreement to the authentic compound
(17.66 min). In addition, the sample was also analyzed via ESI-
MS in the negative and positive ion modes (Figure 2). Note
that the ESI (-) – MS data (Figure 2A), it demonstrated a
molecularion ([M – H]+) at m/z = 609.2 and a fragment ion
at m/z = 299.8. The fragment ion at m/z 299.8 was produced
leaving the rutinoside, suggesting that rutin was converted to
quercetin (Regos et al., 2009; Zhao et al., 2013). The sample
analysis via ESI-MS in the positive ion mode was shown in
Figure 2B, molecular cation was detected mainly in [M +
Na]+ form (m/z 633.2), and minor [M + H]+ (m/z 611.3)
FIGURE 1 | The HPLC chromatograms of the Syringa oblata Lindl. aqueous extract (1) and the rutin standard (2).
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FIGURE 2 | Mass spectra of Syringa oblata Lindl. aqueous extract. (A) MS spectra in negative mode, (B) MS spectra in positive mode.
ion was also detected. The spectrum showed abundant ions at
m/z 303.3 (loss of rutinoside) (Regos et al., 2009; Zhao et al.,
2013). Thus, all of these evidences confirmed the existence of
rutin in Syringa oblata Lindl. aqueous extract. Quantification of
rutin was performed based on the calibration curve which was
obtained by plotting peak areas vs. six different concentrations
of the standard solutions (0.0126, 0.0252, 0.0504, 0.1008,
0.0152, and 0.2016 mg/mL). The calibration curve equation was
y = 3E+07x+93411, R2 = 0.9991. As a result, the mean value
of rutin in the aqueous extract of Syringa oblata Lindl. was
found at 9.9 ± 0.089 mg/g dry weight, with a recovery yield of
101.43± 0.99%.
Effect of Syringa oblata Lindl. Aqueous
Extract and Rutin against Biofilm
Formation In vitro
Minimal inhibitory concentration of Syringa oblata Lindl.
aqueous extract against S. suis ATCC 700794 was determined
as 50 mg/mL. Thereafter, we evaluated the action of Syringa
oblata Lindl. aqueous extract on biofilm growth in vitro. As
reported in Figure 3A, when the culture medium was added
with 1/2 MIC, 1/4 MIC, and 1/8 MIC of Syringa oblata
Lindl. aqueous extract, the biofilms by S. suis were reduced
(p < 0.05). There was no pronounced effect for 1/16 MIC
of Syringa oblata Lindl. aqueous extract on biofilm formation
of S. suis (p > 0.05). We also evaluated the action of rutin
on biofilm growth in vitro. The MIC against S. suis was
0.3125 mg mL−1. Rutin at 1/2 MIC and 1/4 MIC caused a
significantly higher reduction in the biofilm-forming ability of
S. suis compared with positive control (p < 0.05). However,
there was no pronounced effect for 1/16 MIC and 1/8
MIC of rutin on biofilm formation of S. suis (p > 0.05)
(Figure 3B).
Previous studies have shown that sub-MICs of antimicrobial
agents can either increase or decrease biofilm formation by
bacterial pathogens (Pompilio et al., 2010; Bedran et al.,
2014). Our study brought clear evidence that sub-MICs of
Syringa oblata Lindl. aqueous extract significantly decreased
biofilm formation by S. suis. Previous studies have shown that
extracts of Syringa plants mainly contain iridoids, lignans, and
phenylethanoids that have antitumor, antihypertensive, anti-
oxidant, and anti-inflammatory activities. We further provide
evidence that rutin is the effective components of Syringa
oblata Lindl. specifically affects S. suis biofilm. To the best
of our knowledge, it was the first report that sub-MICs of
Syringa oblata Lindl. aqueous extract decreased biofilm formed
by S. suis.
Direct Observation of Biofilm Formation
In vitro by Scanning Electron Microscopy
Scanning electron microscopy analysis was performed to
observe the Syringa oblata Lindl. aqueous extract and rutin
sub-MICs-induced S. suis biofilm formation. Figures 4A,C
shows that the surface of the glass slide covered completely
by a thick biofilm made of aggregates and microcolonies.
However, when the culture medium was added with 1/2
MIC of Syringa oblata Lindl. aqueous extract and rutin,
individual pairs of S. suis and individual short chains of S. suis
attached to the glass slide (Figures 4B,D). Scanning electron
microscopy analysis revealed that 1/2 MIC of Syringa oblata
Lindl. aqueous extract and rutin significantly decreased biofilm
formation.
Differentially Expressed Proteins by
iTRAQ
In the present study, iTRAQ technology was used to compare
the patterns of protein expression at two different conditions
(1/2 MIC of Syringa oblata Lindl. aqueous extract treated and
non-treated cells). A ratio of proteins with >1.5 or <0.67 (p-
value < 0.05) was considered to be differentially expressed.
Based on this criterion, twenty-eight differentially expressed
proteins were determined, 17 (61%) of which were up regulated
and 11 (39%) were significantly suppressed (Table 1). The
results regarding molecular function were as follows: motor
activity (1, 3.6%), catalytic activity (17, 60.7%), DNA binding
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FIGURE 3 | (A) Effect of sub-MICs of Syringa oblata Lindl. aqueous extract on biofilm formation by Streptococcus suis ATCC700794. (B) Effect of sub-MICs of rutin
on biofilm formation by S. suis ATCC700794. Data are expressed as means ± standard deviations. Controls refer to the absence of Syringa oblata Lindl. aqueous
extract. Significant decrease (∗p < 0.05) compared to control bacteria grown in the absence of Syringa oblata Lindl. aqueous extract.
FIGURE 4 | Scanning electron micrographs of S. suis ATCC700794 biofilm following growth in THB supplemented without Syringa oblata Lindl.
aqueous extract and rutin (A,C), or with 1/2 MIC of Syringa oblata Lindl. aqueous extract and rutin (B,D). Controls refer to the absence of Syringa oblata Lindl.
aqueous extract.
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TABLE 1 | iTRAQ identification of differentially expressed proteins.
Accession Proteins Foldchangea
Down-regulated proteins
G7S1J0 Phosphatase 0.618
G7RZ18 Sortase-like protein 0.644
B9WUV5 Transcriptional regulator, DeoR
family
0.527
G7S2M0 DNA gyrase subunit B 0.624
D5AGH9 Antigen-like protein 0.624
G7SHZ3 Bacteriophage protein, putative 0.599
G5KZN4 DNA polymerase IV 0.573
M1VJJ3 CPS6J 0.585
M1VK55 CPS28H 0.568
G5L259 NADP-dependent
glyceraldehyde-3-phosphate
dehydrogenase, putative
0.581
G5KZR3 Glutathione S-transferase 0.658
Up-regulated proteins
G5KZ86 Phosphatidylserine/
phosphatidylglycerophosphate/
cardiolipin synthase-like protein
1.766
J7KIA5 Abortive infection bacteriophage
resistance related protein
1.527
Putative competence-damage
inducible protein
1.739
R4NU85 Phosphoribosylformylglycinamidine
synthase domain-containing protein
1.964
G7SKQ9 CPS16F 2.981
E9NQ13 Putative uncharacterized protein 1.671
G5KZE4 Uncharacterized protein 1.568
M1VRG0 Putative uncharacterized protein 1.654
G7SP92 Putative uncharacterized protein 1.570
G5L3A6 Plasmid replication protein Rep and
AAA-class ATPase domain protein
2.017
R4NW55 CPS16V 2.119
E9NQ29 Helicase 1.756
G7S7E3 Neprilysin (Fragment) 2.259
B0FYB8 ABC superfamily ATP binding
cassette transporter, membrane
protein
2.821
G7SD52 Type I site-specific
restriction-modification system, R
(Restriction) subunit and related
helicase
2.538
G7SM99 Chloramphenicol acetyltransferase 2.862
C6GT52 FAD-dependent pyridine
nucleotide-disulfide oxidoreductase
3.432
G7S7A9
a1/2 MIC of Syringa oblata Lindl. aqueous extract treated vs. non-treated cells.
(5, 17.9%), metal ion binding (2, 7.1%), nucleotide binding
(4, 14.3%), protein binding (1, 3.6%), and unknown molecular
function (10, 35.7%). The results regarding cellular component
were as follows: cytoplasm (4, 14.3%), membrane (7, 25.0%),
cytoskeleton (1, 3.6%), chromosome (1, 3.6%), and unknown
cellular component (18, 64.3%). According to the biological
process, these proteins were classified into following categories:
regulation of biological process (3, 10.7%), response to stimulus
(3, 10.7%), metabolic process (12, 42.9%), cell organization
and biogenesis (1, 3.6%), defense response (1, 3.6%), cellular
homeostasis (1, 3.6%), transport (1, 3.6%), and unknown
biological process (14, 50.0%). The majority of the proteins were
related to catalytic activity and metabolism. A total of four
proteins were classified as hypothetical, and their function is
currently unknown. Additionally, three proteins were classified as
“probable” and their likely identities were based upon homology
to proteins of known function in other related species. For
treated cells, various groups of related proteins were shown to
be significantly up-regulated or down-regulated. These included
those associated with metabolic process. These findings suggested
that 1/2 MIC of Syringa oblata Lindl. aqueous extract treated
cells and non-treated cells were subjected to different pharmic
pressures, which might result in different proteome patterns.
Proteins Involved in Cell Growth and
Metabolism
In the present study, Syringa oblata Lindl. aqueous extract
affected metabolism, for example, DNA gyrase subunit B
(foldchange: 0.62), DNA polymerase IV (fold change: 0.57),
NADP-dependent glyceraldehyde-3-phosphate dehydrogenase
(fold change: 0.58), Phosphatase (fold change: 0.62). The four
proteins were related to cell growth and metabolism. Specifically,
bacterial DNA gyrase is the target of many antibiotics (Oblak
et al., 2007), such as fluoroquinolones.
Proteins Involved in Capsule Expression
Streptococcus suis is a Gram-positive bacterium, and it possesses
the CPS. Most S. suis strains possess a group of CPS synthesis
genes and phenotypically express CPS. Previous studies have also
shown that an S. suis serotype 2 mutant impaired in capsule
expression acquire a biofilm-positive phenotype (Tanabe et al.,
2010). Moreover, a hydrophilic capsule may hinder hydrophobic
structures or components important for biofilm formation by
S. suis (Bonifait et al., 2010). Alternatively, the infection is
aggravated by unencapsulation by promoting the ability of
bacterial cells to adhere to host cells and form thick biofilms
(Benga et al., 2004; Bonifait et al., 2010; Tanabe et al., 2010;
Lakkitjaroen et al., 2011). Many different surface molecules,
including CPS, may play a fundamental role in pneumococcal
biofilm development. Impaired pneumococcal CPS may increase
biofilm formation (Qin et al., 2013). In this study, Syringa oblata
Lindl. aqueous extract affected the CPS synthesis enzymes, for
example, CPS 6J (fold change: 0.59), CPS 28H (fold change: 0.57),
CPS 16F (fold change: 2.98), CPS 16V (fold change: 2.12). We
speculated that Syringa oblata Lindl. aqueous extract might affect
the biosynthesis of the CPS. However, further higher studies are
needed to know the detailed molecular mechanism.
In summary, Syringa oblata Lindl. aqueous extract might be
used as a potential inhibitor for the control of biofilm formation
by S. suis. We found that Syringa oblata Lindl. aqueous extract
affected growth, metabolism and the CPS synthesis enzymes. The
active ingredient of the Syringa oblata Lindl. aqueous extract was
rutin. These data showed a useful starting point for more focused
studies to understand what exactly was going on. In future, the
Frontiers in Pharmacology | www.frontiersin.org 7 January 2017 | Volume 8 | Article 26
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detailed molecular mechanism may provide further insight in this
study.
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